|
1
|
American Diabetes Association, . Standards
of medical care in diabetes-2015 abridged for primary care
providers. Clin Diabetes. 33:97–111. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferrannini E, Baldi S, Frascerra S,
Astiarraga B, Heise T, Bizzotto R, Mari A, Pieber TR and Muscelli
E: Shift to fatty substrate utilization in response to
sodium-glucose cotransporter 2 inhibition in subjects without
diabetes and patients with type 2 diabetes. Diabetes. 65:1190–1195.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nolan CJ, Ruderman NB, Kahn SE, Pedersen O
and Prentki M: Insulin resistance as a physiological defense
against metabolic stress: Implications for the management of
subsets of type 2 diabetes. Diabetes. 64:673–686. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
American Diabetes Association, . Standards
of medical care in diabetes — 2014. Diabetes Care. 37 Suppl
1:S14–S80. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Catapano AL, Graham I, De Backer G,
Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser
U, Pedersen TR, et al: Authors/Task Force Members: 2016 ESC/EAS
guidelines for the management of dyslipidaemias: The task force for
the management of dyslipidaemias of the European Society of
Cardiology (ESC) and European Atherosclerosis Society (EAS)
Developed with the special contribution of the European
Assocciation for Cardiovascular Prevention & Rehabilitation
(EACPR). Atherosclerosis. 253:281–344. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li H, Horke S and Förstermann U: Vascular
oxidative stress, nitric oxide and atherosclerosis.
Atherosclerosis. 237:208–219. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Alexopoulos N, Katritsis D and Raggi P:
Visceral adipose tissue as a source of inflammation and promoter of
atherosclerosis. Atherosclerosis. 233:104–112. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bhakdi S: Pathogenesis of atherosclerosis:
Infectious versus immune pathogenesis. A new concept. Herz.
25:84–86. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Murphy SA, Cannon CP, Blazing MA,
Giugliano RP, White JA, Lokhnygina Y, Reist C, Im K, Bohula EA,
Isaza D, et al: Reduction in total cardiovascular events with
ezetimibe/simvastatin post-acute coronary syndrome: The IMPROVE-IT
Trial. J Am Coll Cardiol. 67:353–361. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Criner GJ, Connett JE, Aaron SD, Albert
RK, Bailey WC, Casaburi R, Cooper JA Jr, Curtis JL, Dransfield MT,
Han MK, et al: COPD Clinical Research Network; Canadian Institutes
of Health Research: Simvastatin for the prevention of exacerbations
in moderate-to-severe COPD. N Engl J Med. 370:2201–2210. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xue L, Zhu XH, Yang XF, Bao XC, Gao XQ,
Qiu YH, Wu Z, Ji XP and Li HW: Effect of pioglitazone combined with
simvastatin on the CD40-CD40 ligand system in rabbits with
atherosclerosis. Eur Rev Med Pharmacol Sci. 19:322–327.
2015.PubMed/NCBI
|
|
12
|
Al Rifai M, Silverman MG, Nasir K, Budoff
MJ, Blankstein R, Szklo M, Katz R, Blumenthal RS and Blaha MJ: The
association of nonalcoholic fatty liver disease, obesity, and
metabolic syndrome, with systemic inflammation and subclinical
atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA).
Atherosclerosis. 239:629–633. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim SH, Pei QM, Jiang P, Yang M, Qian XJ
and Liu JB: Effect of active vitamin D3 on VEGF-induced ADAM33
expression and proliferation in human airway smooth muscle cells:
Implications for asthma treatment. Respir Res. 18:72017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mangge H, Weghuber D, Prassl R, Haara A,
Schnedl W, Postolache TT and Fuchs D: The role of vitamin D in
atherosclerosis inflammation revisited: More a bystander than a
player? Curr Vasc Pharmacol. 13:392–398. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lutgens E, Lievens D, Beckers L, Wijnands
E, Soehnlein O, Zernecke A, Seijkens T, Engel D, Cleutjens J,
Keller AM, et al: Deficient CD40-TRAF6 signaling in leukocytes
prevents atherosclerosis by skewing the immune response toward an
antiinflammatory profile. J Exp Med. 207:391–404. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kotlarz D, Marquardt B, Barøy T, Lee WS,
Konnikova L, Hollizeck S, Magg T, Lehle AS, Walz C, Borggraefe I,
et al: Human TGF-β1 deficiency causes severe inflammatory bowel
disease and encephalopathy. Nat Genet. 50:344–348. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Edwards JP, Hand TW, Morais da Fonseca D,
Glass DD, Belkaid Y and Shevach EM: The GARP/Latent TGF-β1 complex
on Treg cells modulates the induction of peripherally derived Treg
cells during oral tolerance. Eur J Immunol. 46:1480–1489. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gerdes N, Seijkens T, Lievens D, Kuijpers
MJ, Winkels H, Projahn D, Hartwig H, Beckers L, Megens RT, Boon L,
et al: Platelet CD40 exacerbates atherosclerosis by transcellular
activation of endothelial cells and leukocytes. Arterioscler Thromb
Vasc Biol. 36:482–490. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gimbrone MA Jr and García-Cardeña G:
Endothelial cell dysfunction and the pathobiology of
atherosclerosis. Circ Res. 118:620–636. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li Y, Zou N, Wang J, Wang KW, Li FY, Chen
FX, Sun BY and Sun DJ: TGF-β1/Smad3 signaling pathway mediates T-2
toxin-induced decrease of type II collagen in cultured rat
chondrocytes. Toxins (Basel). 9:92017. View Article : Google Scholar
|
|
21
|
Hwangbo C, Tae N, Lee S, Kim O, Park OK,
Kim J, Kwon SH and Lee JH: Syntenin regulates TGF-β1-induced Smad
activation and the epithelial-to-mesenchymal transition by
inhibiting caveolin-mediated TGF-β type I receptor internalization.
Oncogene. 35:389–401. 2016. View Article : Google Scholar : PubMed/NCBI
|
